Published in the Official Gazette the AIFA determines the methods of use and the conditions of administration of the Merck anti-viral pill for the treatment of Covid “in adult patients not hospitalized for Covid 19 with recent onset mild-moderate disease and conditions concomitant clinics that represent specific risk factors “. “The prescription and treatment – reads the determination – must guarantee the administration of the product as early as possible with respect to the onset of symptoms and in any case no later than 5 days from the beginning of the same”. (HANDLE).
breaking latest news © Copyright ANSA